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SUMMARY
OBJECTIVES Naturalistic studies comparing differences in risks across antidepressant agents must take into account factors which
influence selection of specific agents and may be associated with outcomes. We examined predictors of antidepressant choice among VA
patients treated for depression.
METHODS Retrospective cohort study of VA patients with depression diagnoses and a new start of one of the seven most commonly
prescribed antidepressant agents between 1 April 1999 and 30 September 2004 (n¼ 502 179). We examined the relationship between patient
and facility characteristics and new starts of bupropion, citalopram, fluoxetine, mirtazapine, paroxetine, sertraline, and venlafaxine. We also
examined factors associated with new starts only among patients starting selective serotonin reuptake inhibitors (SSRIs).
RESULTS Thirty-three percent of patients starting mirtazapine had at least three outpatient mental health visits in the prior year, compared
to 24% of patients prescribed other antidepressants. Patients starting mirtazapine were also most likely to have received at least two other
psychotropic medications in the prior year. Of the four SSRIs, 40% of the patients receiving sertraline and only 31% of those receiving
fluoxetinewere 65 years or older. A comorbid anxiety disorder (other than post-traumatic stress disorder) was diagnosed in 21% of paroxetine
patients compared with 15% of other SSRI patients.
CONCLUSION Choice of antidepressant medication for depressed VA patients was associated with important differences in demographic
and clinical variables, including psychiatric illness severity, older age, and likelihood of a comorbid anxiety disorder. These findings
emphasize the importance of controlling for selection bias when using observational data to compare risks from or effect of mental health
treatments. Copyright # 2010 John Wiley & Sons, Ltd.
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INTRODUCTION
Researchers, drug safety experts, and policy makers are
increasingly using large clinical observational datasets
to explore potential relationships between medication
use and adverse outcomes. In particular, examining the
relationship between specific medications and tragic,
but rare, outcomes, such as suicide deaths, can often only
be accomplished with large observational datasets.
However, a major limitation in using existing clinical
datasets to assess potential causal links between
treatments and outcomes is treatment selection in
clinical settings. In these settings, treatments are
selected based on physician and patient preferences
rather than being randomly allocated. Thus, patients
who have higher risks for poor outcomes may
preferentially receive specific treatments, potentially
resulting in spurious associations between these treat-
ments and poor outcomes. Because of these challenges,
several large observational studies have inaccurately
identified associations between treatments and outcomes
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(e.g., hormone replacement therapy and reduced
cardiac disease).1
Recently, concerns have emerged that antidepressant
medications which are effective treatments for
depression, might paradoxically increase suicide risks,
particularly in the weeks following treatment initiation
or dosage change. Pharmaceutical company data from
multiple randomized controlled trials of antidepressant
treatment of children, adolescents, and young adults
have indicated increased rates of suicidal thinking and
behaviors among individuals randomized to anti-
depressant treatment. However, the impact on suicide
deaths is less certain.2,3
Because deaths from suicide are rare, large sample
sizes are needed to assess potential associations
between antidepressants and suicide death, and
administrative data have been used for this purpose.
However, to date, these studies have reported mixed
results, potentially because of channeling or treatment
selection biases. To draw valid conclusions based on
observational studies, it is important to understand the
predictors of different choices of antidepressant agent.
Prior studies have indicated that choice of antidepress-
ant may be influenced by physician characteristics such
as specialty or age and by patient characteristics such as
number of previous depressive episodes or education
level.4–7 However, there may be fewer selection biases
when only selective serotonin reuptake inhibitors
(SSRIs) are considered as these medications are thought
to have similar mechanisms of action and to have
comparable efficacy in treating depression.8,9
In this study, we examined whether patient
characteristics readily available in the VA adminis-
trative data were associated with initial choice of an
antidepressant agent in VA patients diagnosed with
depression. The Department of Veterans Affairs
Health System (VA) is the nation’s largest organized
healthcare system and has information systems
offering data for large-scale assessments of treatment
practices and patient outcomes. Although data on pre-
scriber characteristics are not available, data on patient
mental and physical health conditions and psycho-
tropic medication fills are readily available in VA
administrative databases.
We used a unique longitudinal dataset with com-
prehensive diagnosis and pharmacy data for all VA
patients in depression treatment between 1 April 1999
and 30 September 2004 to examine patient and facility
characteristics associated with initial choice of an
antidepressant agent. We hypothesized that patients
receiving different antidepressant agents would differ
significantly in demographic and clinical character-
istics (e.g., age and illness severity) that might also be
associated with treatment outcomes. If verified, this
conclusion has implications for studies using admin-
istrative data to examine relationships between anti-
depressant treatments and outcomes and implication
for quality improvement efforts aimed at standardizing
antidepressant treatment practices.
METHODS
Study population and design
A retrospective cohort study was conducted to evaluate
antidepressant agent choice for new antidepressant
starts among patients diagnosed with depression. Data
were obtained from the VA’s National Registry for
Depression (NARDEP) which was developed by the
VA’s Serious Mental Illness Treatment Resource and
Evaluation Center (SMITREC) in Ann Arbor, Michi-
gan. This study was approved by the Institutional
Review Board of the Veterans Affairs Ann Arbor
Health System. All patients who used the VA between
1 April 1999 and 30 September 2004, and received one
or more depression diagnoses and a new start of one of
the seven most commonly prescribed antidepressants
(bupropion, citalopram, fluoxetine, mirtazapine, par-
oxetine, sertraline, or venlafaxine) were included in the
study. Depression diagnoses were identified using the
International Classification of Disease (9th edition)
[ICD-9] codes: 296.2x, 296.3x, 296.90, 296.99, 298.0,
300.4, 311, 293.83, 301.12, 309.0, or 309.1. Patients
were excluded if they had any of the following
diagnoses during the study period: bipolar I, bipolar II,
schizophrenia, or schizoaffective disorder.
Study variables
Patients’ gender, age, race, ethnicity, and marital status
were ascertained from national VA databases. Patients
were categorized into four age groups of <40, 40–49,
50–64, and 65 years based on their age at the first
antidepressant. Each patient was classified into one of
four racial categories (Black, White, other, or unknown
race), and patients’ ethnicity was defined as Hispanic
or non-Hispanic.
All diagnosis, medication, and utilization data
(except suicide attempt) were based on data during
the 12months prior to first new antidepressant start. We
obtained diagnoses data for post-traumatic stress
disorder (PTSD), personality disorder, major depres-
sion, other anxiety disorder, substance-use disorders
(either alcohol or other substance abuse or depen-
dence), and tobacco-use disorder. Medical comorbidity
was defined as having 0, 1, 2 or 3 comorbidities
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included in the Charlson Comorbidity Index.10
Services utilization data were categorized based on
their distribution: number of psychiatric stays (0, 1,
2), number of outpatient visits (0–3, 4–12, or 13),
number of outpatient mental health visits (0, 1–2, 3)
and having had any psychotherapy visits (based on
CPT codes). We also obtained Medicare use and
the number of psychotropic medications (0, 1, 2)
prescribed in the 12 months prior to new antidepressant
start. The number of psychotropic medications is a
count of psychotropic meds received which includes
drugs for alcohol treatment, anxiety meds, hypnotics,
mood stabilizers, antidepressants, antipsychotics,
stimulants, and anticolinesterase medications. Facility
variables included geographic region of the country
(Northeast, West, Midwest, or South) and location
in an urban versus rural area based on Metropolitan
Statistical Area designation. Suicide attempts were
obtained based on ICD-9 codes E950-E959 and ICD-
10 codes X60-X84 and Y87.0 using the data during
prior 3 years.11
Antidepressant agents
Our primary outcome of interest was choice of anti-
depressant agent for new antidepressant starts follow-
ing a 6-month clean period without any antidepressant
fills or supply. We assessed new starts of seven of the
most commonly prescribed antidepressants, four in
the SSRI class (fluoxetine, sertraline, paroxetine, and
citalopram), and three dual action alternative anti-
depressants (venlafaxine, bupropion, and mirtazapine).
We did not include older antidepressants such as
tricyclic antidepressants (TCAs) and monoamine
oxidase inhibitors (MAOI) because they are used far
less frequently. The seven antidepressants comprise
90% of the antidepressant prescriptions filled in the VA
during the study period. The clean period had to be
clean of all antidepressants including tricyclics. Time
since depression diagnosis to the first antidepressant
start was also assessed, with truncation at 2 years.
Data analyses
Descriptive statistics were calculated with percentages
for categorical variables and means and standard
deviations for continuous variables. Predictors of
antidepressant choice were examined using multi-
nomial logistic regression models.12 To account for
potential correlation within facility, we obtained robust
standard errors with clustering by facility using Huber/
White sandwich estimators.13 Because much of the
variation in choice of antidepressant agent for new
starts may be due to small area practice patterns, we
conducted a sensitivity analysis, in which a model was
fit with facilities included as dummy variables, rather
than including the facility-level variables of region and
urban facility. All analyses were conducted using
Stata10.1 (College Station, TX).
RESULTS
Patient characteristics associated with
antidepressant choice
Of the patients diagnosed with depression who initiated
a new antidepressant treatment, 502 179 patients
started one of the seven antidepressants. Of them,
81 112 patients (16.2%) had at least one other episode
of a new antidepressant start. We focused the analyses
primarily on the first new antidepressant starts. The
majority of the patients were male and non-Hispanic
White.
The distribution of the antidepressant agent types is
shown by fiscal year in Table 1. Of the seven
antidepressants, the majority were given an SSRI:
sertraline was prescribed in 27.0% of patients,
citalopram in 26.1%, fluoxetine in 14.0%, and
paroxetine in 13.3%. Of the non-SSRIs, bupropion
was prescribed more often (10.9%) than mirtazapine
(4.2%) or venlafaxine (4.4%). Rates of bupriopion
prescription remained similar across years, but other
antidepressants showed differing prescription trends
over the study years. Initial prescriptions of mirtaza-
pine, venlafaxine, and citalopram tended to increase
over study years, while prescriptions of sertraline and
paroxetine decreased.
Table 2 shows patient characteristics associated
with each of the seven antidepressants. Due to the
large sample size, the choice of antidepressant had
statistically significant associations with many pre-
dictor variables. We emphasize those predictors with
noticeably different distributions for an antidepressant
choice.
We found that bupropion was prescribed less often
to older patients; 16% of bupropion fills were for
patients65 years compared to 29.5% or more of fills
of other antidepressants. Not surprisingly, given its
dual indication for depression and smoking cessation,
36.2% of bupropion fills were prescribed to depressed
patients with comorbid tobacco use disorder com-
pared to 17.7% or less of fills of other antidepress-
ants. For each antidepressant agent, the proportion of
patients with comorbid psychiatric illnesses such as
anxiety disorder was substantial; however, a sub-
stantially larger proportion of patients receiving
Copyright # 2010 John Wiley & Sons, Ltd. Pharmacoepidemiology and Drug Safety, 2010; 19: 1049–1056
DOI: 10.1002/pds
predictors of antidepressant initiation 1051
mirtazapine or venlafaxine had major depression
diagnoses rather than other depressive disorder
diagnoses, and a larger proportion of patients
receiving mirtazapine had concurrent substance
abuse than those receiving fills of other antidepress-
ants. Mirtazapine was also preferentially prescribed
to patients with higher levels of concurrent medical
conditions, to those with previous psychiatric
inpatient hospitalizations, to those with outpatient
mental health visits and to those with psychotherapy
visits in prior year. Of the four SSRIs, meaningful
differences in prescription patterns were seen with
age, with SSRI agents other than fluoxetine being
filled more often by patients 65 years or older (37% or
more of fills compared to 31% of fluoxetine fills).
Paroxetine was filled more often by patients with
other anxiety disorders (21% of fills) than were other
SSRI agents (15% or less of fills).
Covariate adjusted predictors of seven commonly
used antidepressant agents
Table 3 gives the relative risk ratios (RRRs) based on
the multinomial logistic model predicting antidepress-
ant agent selection, adjusting for facility as well as
patient variables listed in the table. Sertraline was the
reference category for all RRRs because it had the
largest sample size. We emphasize the predictors with
RRRs of >2.0 or <0.5, but because indications for
the various SSRI agents are potentially more similar,
we considered RRRs of close to or<0.75 (or>1.33) to
be potentially meaningful predictors of agent choice
within the SSRI class.
Patient age and anxiety disorder remained as
important patient characteristics associated with the
choice of initial antidepressant agent even after
adjusting for other variables. Patients with other
anxiety disorder diagnoses were 1.68 times (95%
CI¼ 1.64–1.72) more likely to start on paroxetine
than sertraline. Relative to younger patients (<40
years), older (65 years) patients were 0.37 times
(95% CI¼ 0.35–0.38) less likely to have started on
bupropion than sertraline as an initial antidepressant,
and of the SSRIs, older patients were 0.70 times
(95% CI¼ 0.67–0.73) less likely to have started on
fluoxetine than sertraline. Black patients were less
likely to start on paroxetine (RRR¼ 0.80; 95%
CI¼ 0.77–0.82) than sertraline, while Hispanics
were more likely to start on paroxetine than sertraline
(RRR¼ 1.61; 95% CI¼ 1.54–1.67). We explored
whether increased use of paroxetine in Hispanic
patients was associated with prior psychotherapy
visits or age, and found paroxetine to be used more
often in older Hispanics; older Hispanics (65 years)
were 2.0 times (p< 0.001) more likely than younger
Hispanics (<40 years) to start on paroxetine than
sertraline. Patients with PTSD were also more likely
to start on sertraline or mirtazapine than other
antidepressants. Patients with tobacco-use disorder
were 3.16 times (95% CI¼ 3.08–3.24) more likely to
be prescribed bupropion than sertraline, while no
other agents showed notable RRR for tobacco use
disorder.
Although unadjusted analyses showed increased use
of non-SSRIs than SSRIs in those with psychotherapy
in prior year, the differences did not remain after
adjusting for covariates. All non-SSRIs were more
likely to be filled than sertraline or other SSRIs by
those with at least one outpatient mental health visit
in the year prior to the index prescription, and in
particular, mirtazapine was more likely to be filled than
sertraline by 2.93 times in those with one to two visits
and 3.68 times in those with at least three visits. On the
other hand, patients with 13 or more total outpatient
visits were 0.49 times less likely to have started on
venlaflaxine than sertraline. Of the SSRIs, fluoxetine
and paroxetine, compared with sertraline, were
significantly less likely to be prescribed for those with
Table 1. Distribution of seven first antidepressant agents by fiscal year for the VA patients diagnosed with depression who received at least one prescription to





Serotonin reuptake inhibitor (SSRI) Non-SSRI
Citalopram Fluoxetine Paroxetine Sertraline Bupropion Mirtazapine Venlafaxine
1999y 23 241 2732 (11.8) 4069 (17.5) 3863 (16.6) 8947 (38.5) 2580 (11.1) 413 (1.8) 637 (2.7)
2000 59 841 11 772 (19.7) 8331 (13.9) 9860 (16.5) 19 962 (33.4) 6313 (10.6) 1590 (2.7) 2013 (3.4)
2001 81 553 21 299 (26.1) 9516 (11.7) 11 935 (14.6) 23 898 (29.3) 8843 (10.8) 3026 (3.7) 3036 (3.7)
2002 100 676 31 645 (31.4) 10 658 (10.6) 14 278 (14.2) 25 208 (25.0) 10 241 (10.2) 4506 (4.4) 4140 (4.1)
2003 115 684 32 527 (28.1) 16 907 (14.6) 14 290 (12.4) 28 522 (24.7) 12 338 (10.7) 5447 (4.7) 5653 (4.9)
2004 121 184 31 308 (25.8) 21 018 (17.3) 12 701 (10.5) 29 118 (24.0) 14 377 (11.9) 6165 (5.0) 6497 (5.4)
N (%) 502 179 131 283 (26.1) 70 499 (14.0) 66 927 (13.3) 135 655 (27.0) 54 692 (10.9) 21 147 (4.2) 21 976 (4.4)
Fiscal year begins on 1 October and ends on 30 September of the following year.
y1999 data were only from mid fiscal year.
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Table 2. Patient characteristics by the first antidepressant agent filledy
All patients
(n¼ 502 179)
















<40 49 807 (9.9) 12 003 (9.1) 7933 (11.3) 6571 (9.8) 11 662 (8.6) 7109 (13.0) 1797 (8.5) 2732 (12.4)
40–49 84 648 (16.9) 20 963 (16.0) 12 326 (17.5) 10 672 (16.0) 20 109 (14.8) 12 579 (23.0) 3879 (18.3) 4120 (18.8)
50–64 196 669 (39.2) 50 412 (38.4) 28 637 (40.6) 24 562 (36.7) 49 780 (36.7) 26 211 (47.9) 8419 (39.8) 8648 (39.4)
65þ 171 055 (34.1) 47 905 (36.5) 21 603 (30.6) 25 122 (37.5) 54 104 (39.9) 8793 (16.1) 7052 (33.4) 6476 (29.5)
Male 460 603 (91.7) 120 702 (91.9) 63 517 (90.1) 61 286 (91.6) 125 324 (92.4) 49 962 (91.4) 20 225 (95.6) 19 587 (89.1)
Female 41 576 (8.3) 10 581 (8.1) 6982 (9.9) 5641 (8.4) 10 331 (7.6) 4730 (8.7) 922 (4.4) 2389 (10.9)
Race
White 378 850 (75.4) 99 845 (76.1) 52 253 (74.1) 52 415 (78.3) 102 582 (75.6) 39 505 (72.2) 15 197 (71.9) 17 053 (77.6)
Black 64 413 (12.8) 16 435 (12.5) 8711 (12.4) 7144 (10.7) 18 861 (13.9) 7341 (13.4) 3897 (18.9) 1934 (8.8)
Other 10 555 (2.1) 2930 (2.2) 1582 (2.2) 1254 (1.9) 2631 (1.9) 1250 (2.3) 480 (2.3) 428 (2.0)
Unknown 48 361 (9.6) 12 073 (9.2) 7953 (11.3) 6114 (9.1) 11 581 (8.5) 6596 (12.1) 1483 (7.0) 2561 (11.7)
Hispanic 24 653 (4.9) 6548 (5.0) 4115 (5.8) 4398 (6.6) 5796 (4.3) 2148 (3.9) 832 (3.9) 816 (3.7)
SA: Alcohol 60 190 (12.0) 15 102 (11.5) 8208 (11.6) 7278 (10.9) 14 981 (11.0) 8277 (15.1) 4056 (19.2) 2288 (10.4)
SA: Drugs 41 804 (8.3) 10 191 (7.8) 5559 (7.9) 4895 (7.3) 10 116 (7.5) 5984 (10.9) 3326 (15.7) 1733 (7.9)
PTSD 66 494 (13.2) 17 590 (13.4) 8286 (11.8) 7689 (11.5) 17 741 (13.1) 7685 (14.1) 4564 (21.6) 2939 (13.4)
Major depression 104 900 (20.9) 26 992 (20.6) 14 159 (20.1) 12 344 (18.4) 25 154 (18.5) 13 156 (24.1) 6588 (31.2) 6507 (29.6)
Other anxiety disorder 76 547 (15.2) 20 078 (15.3) 8399 (11.9) 14 277 (21.3) 18 933 (14.0) 6900 (12.6) 4098 (19.4) 3862 (17.6)
Personality disorder 10 342 (2.1) 2459 (1.9) 1409 (2.0) 1395 (2.1) 2457 (1.8) 1339 (2.5) 695 (3.3) 588 (2.7)
Tobacco-use disorder 82 701 (16.5) 18 908 (14.4) 9953 (14.1) 8933 (13.4) 18 438 (13.6) 19 774 (36.2) 3743 (17.7) 2952 (13.4)
Suicide attempt 2000 (0.4) 483 (0.4) 242 (0.3) 227 (0.3) 523 (0.4) 229 (0.4) 170 (0.8) 126 (0.6)
No. of Charlson comorbidities
0 273 435 (54.5) 68 434 (52.1) 41 039 (58.2) 37 502 (56.0) 69 884 (51.5) 32 285 (59.0) 11 091 (52.5) 13 193 (60.0)
1 138 984 (27.7) 36 806 (28.0) 18 711 (26.5) 18 425 (27.5) 38 622 (28.5) 14 910 (27.3) 5770 (27.3) 5740 (26.1)
2 56 654 (11.3) 16 078 (12.3) 7066 (10.0) 7203 (10.8) 16 499 (12.2) 5154 (9.4) 2619 (12.4) 2035 (9.3)
3þ 33 106 (6.6) 9965 (7.6) 3683 (5.2) 3790 (5.7) 10 650 (7.9) 2343 (4.3) 1667 (7.9) 1008 (4.6)
No. of psych stays
0 468 191 (93.2) 122 897 (93.6) 66 342 (94.1) 62 993 (94.1) 126 748 (93.4) 50 814 (92.9) 18 295 (86.5) 20 102 (91.5)
1 25 550 (5.1) 6311 (4.8) 3169 (4.5) 2982 (4.5) 6651 (4.9) 2836 (5.2) 2100 (9.9) 1501 (6.8)
2þ 8438 (1.7) 2075 (1.6) 988 (1.4) 952 (1.4) 2256 (1.7) 1042 (1.9) 752 (3.6) 372 (1.7)
No. of outpatient visits
0–3 158 205 (31.5) 36 711 (28.0) 25 135 (35.7) 24 621 (36.8) 42 532 (31.4) 15 305 (28.0) 5007 (23.7) 8894 (40.5)
4–12 199 032 (39.6) 52 688 (40.1) 27 668 (39.3) 25 853 (38.6) 53 935 (39.8) 22 638 (41.4) 8202 (38.8) 8048 (36.6)
13þ 144 942 (28.9) 41 884 (31.9) 17 696 (25.1) 16 453 (24.6) 39 188 (28.9) 16 749 (30.6) 7938 (37.5) 5034 (22.9)
No. of outpatient mental health visits
0 239 628 (47.7) 62 060 (47.3) 35 442 (53.0) 35 442 (53.0) 71 916 (53.0) 19 677 (36.0) 5182 (24.5) 8718 (39.7)
1–2 170 166 (33.9) 45 580 (34.7) 20 792 (31.1) 20 792 (31.1) 41 648 (30.7) 21 677 (39.6) 9034 (42.7) 8887 (40.4)
3þ 92 385 (18.4) 23 643 (18.0) 10 693 (16.0) 10 693 (16.0) 22 091 (16.3) 13 338 (24.4) 6931 (32.8) 4371 (19.9)
No. of psych meds
0 266 596 (53.1) 68 182 (51.9) 39 750 (56.4) 35 756 (53.4) 74 666 (55.0) 29 200 (53.4) 9070 (42.9) 9972 (45.4)
1 151 125 (30.1) 40 304 (30.7) 20 543 (29.1) 20 294 (30.3) 40 514 (29.9) 15 947 (29.2) 6530 (30.9) 6993 (31.8)
2þ 84 458 (16.8) 22 797 (17.4) 10 206 (14.5) 10 877 (16.3) 20 475 (15.1) 9545 (17.5) 5547 (26.2) 5011 (22.8)
Medicare 144 278 (28.7) 38 186 (29.1) 18 447 (26.2) 21 670 (32.4) 44 304 (32.7) 8980 (16.4) 6229 (29.5) 6462 (29.4)
Psychotherapy visit 104 484 (20.8) 26 796 (20.4) 13 067 (18.5) 12 425 (18.6) 25 454 (18.8) 14 915 (27.3) 6946 (32.9) 4881 (22.2)
Region
Northeast 95 852 (19.1) 22 855 (17.4) 12 870 (18.3) 13 825 (20.7) 28 590 (21.1) 3794 (17.9) 3794 (17.9) 3910 (17.8)
Midwest 112 977 (22.5) 29 060 (22.1) 12 739 (18.1) 15 873 (23.7) 32 079 (23.7) 5845 (27.6) 5845 (27.6) 5164 (23.5)
South 193 540 (38.5) 50 308 (38.3) 26 871 (38.1) 25 204 (37.7) 54 999 (40.5) 7623 (36.1) 7623 (36.1) 8487 (38.6)
West 99 810 (19.9) 29 060 (22.1) 18 019 (25.6) 12 025 (18.0) 19 987 (14.7) 3885 (18.4) 3885 (18.4) 4415 (20.1)
Urban facility 452 354 (90.1) 119 939 (91.4) 63 093 (89.5) 60 305 (90.1) 121 316 (89.4) 48 924 (89.4) 18 944 (89.6) 19 833 (90.2)
Days since diagnosis 10 (448) 5 (403) 4 (407) 7 (406) 5 (354) 73 (715) 71 (730) 26 (453)
Values are all n (%), except days since diagnosis which is median (inter-quartile range).
SA, substance abuse; PTSD, post-traumatic stress disorder.
Days since first depression diagnosis (cohort entry) to the first new start of one of seven antidepressant agents, truncated at 730 days.
yAll variables are significantly different across groups (p< 0.0001).
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three or more comorbid conditions (RRR¼ 0.75 for
fluoxetine and 0.78 for paroxetine) or for those with
13 or more outpatient visits in the year prior to the
index prescription (RRR¼ 0.79 for fluoxetine and
0.70 for paroxetine compared to sertraline).
Significant variation across geographic regions
and fiscal year remained after adjusting for patient
demographics and other covariates. For regional and
yearly variation, we note variation with an RRR <0.75
(or >1.33). Compared with the western region, all
other regions were less likely to prescribe bupropion
and venlafaxine than sertraline, and the northeast
region was less likely to prescribe mirtazapine than
sertraline. Of the SSRIs, compared with the Western
Table 3. Adjusted relative risk ratios [RRR (95% CI)] for the type of antidepressant agents with sertraline as the reference anti-depressant
Serotonin reuptake inhibitor (SSRI) Non-SSRI
Citalopram Fluoxetine Paroxetine Bupropion Mirtazapine Venlafaxine
Age (vs. <40 years)
40–49 years 1.02 (0.99–1.05) 0.97 (0.93–1.01) 0.97 (0.94–1.01) 0.94 (0.90–0.98) 1.11 (1.05–1.18) 0.99 (0.94–1.05)
50–64 years 0.96 (0.93–0.99) 0.93 (0.90–0.96)z 0.93 (0.90–0.97)z 0.83 (0.80–0.86)z 1.01 (0.95–1.07) 0.86 (0.82–0.91)z
65þ years 0.92 (0.89–0.95)z 0.70 (0.67–0.73)z 0.83 (0.80–0.87)z 0.37 (0.35–0.38)z 1.11 (1.03–1.18) 0.59 (0.56–0.63)z
Male (vs. Female) 0.99 (0.96–1.02) 0.89 (0.86–0.92)z 0.95 (0.92–0.99) 1.17 (1.12–1.21)z 1.77 (1.64–1.90)z 0.80 (0.76–0.84)z
Race (vs. White)
Black 0.85 (0.83–0.87)z 0.86 (0.83–0.88)z 0.80 (0.77–0.82)z 0.76 (0.74–0.79)z 1.11 (1.07–1.16)z 0.53 (0.50, 0.56)z
Other 0.99 (0.94–1.05) 0.97 (0.91–1.04) 0.89 (0.83–0.95) 0.93 (0.87–0.99) 1.00 (0.90–1.10) 0.83 (0.75, 0.93)
Unknown 0.93 (0.90–0.96)z 0.94 (0.91–0.98) 0.94 (0.91–0.97) 1.01 (0.97–1.04) 0.86 (0.81–0.91)z 0.93 (0.88–0.98)
Hispanic 1.02 (0.98–1.06) 1.25 (1.20–1.31)z 1.61 (1.54–1.67)z 0.82 (0.78–0.86)z 0.78 (0.73–0.85)z 0.74 (0.69–0.80)z
Alcohol abuse 1.00 (0.97–1.03) 1.04 (1.00–1.07) 1.02 (0.98–1.05) 0.79 (0.76–0.82)z 1.04 (0.98–1.09) 0.76 (0.72–0.80)z
Drug abuse 0.98 (0.94–1.01) 1.06 (1.01–1.11) 1.08 (1.03–1.13) 0.98 (0.94–1.02) 1.19 (1.11–1.26)z 0.93 (0.87–0.99)
PTSD 0.87 (0.85–0.89)z 0.76 (0.73–0.78)z 0.83 (0.81–0.86)z 0.65 (0.63–0.67)z 0.99 (0.95–1.03) 0.70 (0.67–0.74)z
Major depression 1.07 (1.04–1.09)z 1.08 (1.05–1.11)z 0.98 (0.96–1.01) 1.06 (1.04–1.09)z 1.36 (1.32–1.41)z 1.53 (1.48–1.59)z
Other anxiety disorder 1.05 (1.03–1.08)z 0.84 (0.82–0.86)z 1.68 (1.64–1.72)z 0.73 (0.71–0.75)z 1.12 (1.08–1.17)z 1.08 (1.04–1.12)z
Personality disorder 0.99 (0.93–1.05) 1.11 (1.03–1.19) 1.14 (1.07–1.23)z 0.93 (0.86–0.99) 0.97 (0.89–1.07) 1.11 (1.01–1.22)
Tobacco-use disorder 1.00 (0.97–1.02) 1.00 (0.98–1.03) 1.02 (0.99–1.05) 3.16 (3.08–3.24)z 1.06 (1.02–1.11) 0.97 (0.93–1.01)
Suicide attempt 0.90 (0.80–1.03) 0.83 (0.71–0.97) 0.90 (0.76–1.05) 0.80 (0.68–0.94) 1.09 (0.90–1.31) 1.01 (0.83–1.24)
No. of Charlson Comorbidities
1 (vs. none) 0.98 (0.96–0.99) 0.92 (0.90–0.94)z 0.95 (0.93–0.97)z 0.94 (0.92–0.97)z 0.94 (0.90–0.97)z 0.95 (0.92–0.99)
2 (vs. none) 0.99 (0.96–1.01) 0.87 (0.84–0.89)z 0.91 (0.88–0.94)z 0.82 (0.79–0.86)z 0.96 (0.92–1.01) 0.87 (0.83–0.92)z
3þ (vs. none) 0.95 (0.92–0.98) 0.75 (0.71–0.78)z 0.78 (0.74–0.81)z 0.64 (0.61–0.68)z 0.95 (0.89–1.01) 0.74 (0.69–0.80)z
No. of psych inpatient stays
1 (vs. none) 0.98 (0.94–1.02) 0.84 (0.80–0.88)z 0.86 (0.82–0.91)z 0.74 (0.70–0.78)z 1.39 (1.30–1.48)z 1.30 (1.21–1.39)z
2þ (vs. none) 0.96 (0.90–1.03) 0.81 (0.74–0.88)z 0.84 (0.77–0.91)z 0.65 (0.60–0.71)z 1.16 (1.05–1.29) 1.16 (1.03–1.32)
No. of outpatient visits
4–12 (vs. 0–3) 1.10 (1.08–1.12)z 0.85 (0.83–0.87)z 0.80 (0.78–0.82)z 0.91 (0.89–0.94)z 0.91 (0.87–0.94)z 0.61 (0.59–0.63)z
13þ (vs. 0–3) 1.21 (1.18–1.24)z 0.79 (0.77–0.81)z 0.70 (0.68–0.72)z 0.88 (0.85–0.91)z 0.94 (0.89–0.98) 0.49 (0.47–0.52)z
No. of outpatient mental health visits
1–2 (vs. none) 1.29 (1.27–1.32)z 1.04 (1.01–1.06) 0.99 (0.97–1.01) 1.80 (1.75–1.85)z 2.93 (2.81–3.05)z 1.69 (1.63–1.76)z
3þ (vs. none) 1.24 (1.20–1.29)z 1.06 (1.02–1.11)z 0.99 (0.95–1.04) 1.92 (1.84–2.01)z 3.68 (3.47–3.91)z 1.98 (1.86–2.11)z
No. of other psychotropic medications
1 (vs. 0) 1.06 (1.05–1.08)z 1.01 (0.99–1.03) 1.02 (1.00–1.05) 0.95 (0.93–0.97)z 1.05 (1.02–1.09) 1.27 (1.23–1.32)z
2þ (vs. 0) 1.15 (1.13–1.18)z 1.05 (1.02–1.08)z 1.08 (1.05–1.12)z 1.03 (0.99–1.06) 1.43 (1.38–1.49)z 1.82 (1.75–1.90)z
Psychotherapy 0.94 (0.91–0.97)z 1.01 (0.98–1.04) 1.01 (0.98–1.05) 1.03 (1.00–1.07) 0.90 (0.86–0.94)z 0.97 (0.93–1.02)
Medicare use 0.92 (0.90–0.95)z 0.98 (0.95–1.00) 1.09 (1.06–1.12)z 0.90 (0.87–0.93)z 1.13 (1.09–1.18)z 1.29 (1.24–1.35)z
Region (vs. West)
Northeast 0.56 (0.55–0.58)z 0.52 (0.51–0.54)z 0.81 (0.79–0.84)z 0.63 (0.60–0.65)z 0.64 (0.61–0.67)z 0.63 (0.60–0.67)z
Central 0.64 (0.63–0.66)z 0.45 (0.44–0.46)z 0.82 (0.79–0.84)z 0.63 (0.61–0.65)z 0.95 (0.91–0.99) 0.73 (0.69–0.76)z
South 0.64 (0.62–0.65)z 0.55 (0.53–0.56)z 0.75 (0.72–0.77)z 0.62 (0.60–0.64)z 0.74 (0.71–0.77)z 0.73 (0.70–0.76)z
Urban facility 1.22 (1.19–1.25)z 0.98 (0.95–1.01) 1.10 (1.06–1.13)z 1.04 (1.01–1.08) 0.99 (0.94–1.04) 1.13 (1.08–1.19)z
Fiscal year of new start
2000 (vs. 1999) 1.98 (1.89–2.08)z 0.92 (0.88–0.97) 1.13 (1.08–1.18)z 1.12 (1.06–1.18)z 1.83 (1.64–2.05)z 1.47 (1.34–1.61)z
2001 (vs. 1999) 3.11 (2.97–3.26)z 0.88 (0.84–0.92)z 1.13 (1.09–1.19)z 1.33 (1.27–1.40)z 3.23 (2.90–3.59)z 1.96 (1.79–2.14)z
2002 (vs. 1999) 4.45 (4.25–4.66)z 0.94 (0.90–0.98) 1.28 (1.23–1.34)z 1.44 (1.37–1.52)z 4.80 (4.32–5.33)z 2.62 (2.40–2.86)z
2003 (vs. 1999) 4.07 (3.89–4.26)z 1.31 (1.26–1.37)z 1.14 (1.10–1.19)z 1.49 (1.41–1.56)z 5.28 (4.76–5.86)z 3.27 (3.00–3.56)z
2004 (vs. 1999) 3.80 (3.63–3.98)z 1.59 (1.52–1.66)z 1.00 (0.96–1.04) 1.59 (1.51–1.67)z 5.76 (5.20–6.39)z 3.68 (3.38–4.01)z
Days since diagnosisy 0.99 (0.99–0.99)z 1.01 (1.01–1.02)z 1.02 (1.02–1.02)z 1.08 (1.07–1.08)z 1.04 (1.04–1.05)z 1.02 (1.02–1.03)z
PTSD, post traumatic stress disorder.
yDays (in 100 day units) since first depression diagnosis (cohort entry) to first new start of one of the seven antidepressant agents.
p< 0.05; zp< 0.001.
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region, all other regions were significantly less likely to
prescribe citalopram and fluoxetine than sertraline.
Although not markedly different, urban facilities were
more likely to prescribe citalopram (RRR¼ 1.22; 95%
CI¼ 1.19–1.25) than sertraline. Lastly, the choice of
SSRI agent varied significantly by year after adjusting
for covariates, with mirtazapine, venlafaxine and
citalopram more likely to be prescribed toward later
years than sertraline. However, when separate models
were fit by each fiscal year, factors associated with
initial choice of antidepressants, including variation
associated with region of the facility, remained similar
across years as shown by similar estimates of RRRs
especially for those with clinically meaningful and
statistically significant associations.
DISCUSSION
We found several patient characteristics to be strongly
associated with choice of antidepressant for first new
starts after adjusting for potential variation due to
facility variables. Among the seven most commonly
prescribed antidepressants, patients who had a new
start of mirtazapine had a higher burden of psychiatric
illness, patients prescribed sertraline were more likely
to be over 65 years of age, and patients prescribed
paroxetine were more likely to have a comorbid
anxiety disorder. These patient characteristics have
also been associated with depression outcomes,
including suicide risk.14–16 In addition, as expected,
due to its dual indication for depression and cessation
of smoking, patients prescribed bupropion had a higher
rate of tobacco use disorder.
In patients with mental health visits, non-SSRIs were
used more frequently than SSRIs as the initial choice
of antidepressant treatment. This could be due either
to increased severity of the underlying depressive
disorder or that psychiatrists prefer first-line use of
non-SSRIs. Though we cannot tell this apart based on
the administrative data, increased uses of mirtazapine
and venlafaxine were associated with other measures
of increased severity, including major depression or
number of psychotropic medications. And days since
depression diagnosis to new start of an antidepressant
were longer for non-SSRIs than SSRIs. These suggest
that mirtazapine and venlafaxine are not likely the
psychiatrists’ preferred first line of antidepressants, but
rather their use is associated with increased severity of
depression.
SSRIs are generally thought to have similar
indications and effectiveness8,9; however, patient
characteristics were associated with selection of the
four SSRIs as well. Elderly patients were less likely to
start on fluoxetine than other SSRIs compared with
younger patients. This may be due to the greater
number of known drug–drug interactions with fluox-
etine compared with sertraline or citalopram. Elderly
patients may also be less likely to receive fluoxetine
because of clinicians’ concerns about its long half life,
and the possibility of higher medication blood levels
over time if it is taken regularly but metabolized more
slowly.14 Paroxetine was more likely to be used in
patients with anxiety. Association of antidepressant
choice with these patient factors is a concern when
using observational data to assess the effectiveness or
adverse effects of different treatments. For example,
anxiety has been shown to be associated with
suicide,15,16 and if paroxetine were more likely to be
prescribed to patients with anxiety, this may result in a
potentially misleading conclusion of paroxetine being
more likely to be associated with suicide than other
SSRIs.
There was considerable regional variation in the
antidepressant prescription pattern, even among the
four SSRIs and after adjusting for patient character-
istics reflecting potential illness severity. Citalopram
and fluoxetine, compared with sertraline, were signi-
ficantly more likely to be prescribed in the Western
region. In addition, urban facilities were more likely
to prescribe citalopram than sertraline. This reflects
variations in regional practices, but also suggests that
if different SSRIs were associated with differences
in patient outcomes or different tolerability in certain
patient subgroups, further standardizing practices
across regions might improve care.
While this study offers a nationally representative
longitudinal cohort of depressed VA patients, there are
several important limitations. The study involves VA
patients, of which about 90% are male. In the general
population, females represent a large proportion of
antidepressant drug users. Though we have no reason
to believe that the observed relationships between
patient characteristics and the choices of antidepress-
ants in this population would be different in the general
population or in the female population, the results need
to be verified. Because we used administrative data,
we lacked potential key variables that may explain
variation in practice patterns, such as costs of anti-
depressants and provider characteristics. However,
because of generous VA pharmacy coverage, cost may
be less of a factor in antidepressant choice in the VA
than in many other settings. We also did not have
information on distant prior antidepressant use that
may have been a factor in the antidepressant selection,
if patients told prescribing physicians of their previous
experiences with a particular agent. Lastly, the study is
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limited to seven antidepressants and four SSRIs,
though these seven agents make up 90% of the
antidepressant prescriptions at the VA.
Our results highlight the importance of addressing
selection bias when conducting comparative studies of
antidepressants using observational pharmacoepide-
miologic data. Several patient factors are shown to be
associated with variation in initial antidepressant
choice for VA patients newly treated for depression,
including factors which are associated with poorer
patient treatment outcomes such as age and concurrent
anxiety disorder. In particular, we find the increased
use of paroxetine in patients with comorbid anxiety.
Our study also showed bupropion to be associated with
tobacco addiction. Studies may find bupropion to be
associated with decreased risks when this could be due
to its use for smoking cessation in those with mild
depression. The association between potential pre-
dictors of patient outcomes and the choice of an agent
seen even among the four most commonly prescribed
SSRIs further emphases the importance of controlling
for selection bias not only when making comparisons
between SSRIs and non-SSRIs, but even within a drug
class. Controlling for potential biases is inherently
more difficult in observational studies and in particular
with studies using administrative data because the data
are not collected for research purposes and thus under-
reporting of potential covariates of the study can be
common. For future studies examining antidepressant
use and various outcomes using observational data,
particular attention needs to be paid to the strong
predictors of antidepressant initiation shown in our
study. Study results also suggest that reducing regional
variation in antidepressant prescribing practices may
be a potential area of quality improvement within
the VA.
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KEY POINTS
 Choice of new antidepressant medication for
depressed VA patients was associated with patient
characteristics predictive of treatment outcomes,
including psychiatric illness severity, age, and
likelihood of a comorbid anxiety disorder.
 It is important to control for selection bias when
using observational data to compare risks from or
effect of mental health treatments associated with
antidepressant agents.
 Regional variation in the antidepressant choice is
substantial in the depressed VA patients.
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